预约演示
更新于：2025-03-25
Voclosporin
伏环孢素
更新于：2025-03-25
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2021-01-22), |
最高研发阶段(中国)临床3期 |
特殊审评快速通道 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C63H111N11O12 |
InChIKeyBICRTLVBTLFLRD-PTWUADNWSA-N |
CAS号515814-01-4 |
Sequence Code 13844772
关联
37
项与 伏环孢素 相关的临床试验NCT05962788
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Voclosporin in Adolescent Subjects with Lupus Nephritis
CTR20234324
评价伏环孢素治疗活动性狼疮肾炎患者的有效性和安全性—多中心、随机、双盲、安慰剂平行对照III期临床研究
CTR20234019
伏环孢素软胶囊的生物等效性研究
100 项与 伏环孢素 相关的临床结果
登录后查看更多信息
100 项与 伏环孢素 相关的转化医学
登录后查看更多信息
100 项与 伏环孢素 相关的专利（医药）
登录后查看更多信息
152
项与 伏环孢素 相关的文献（医药）2025-03-04EXPERT OPINION ON INVESTIGATIONAL DRUGS
A focused report on IFN-1 targeted therapies for lupus erythematosus
Review
作者: Furie, Richard ; Vashistha, Himanshu ; Bhatt, Anushka ; Gupta, Pramiti
INTRODUCTION:
Patients with Systemic Lupus Erythematosus (SLE) experience varied manifestations and unpredictable flares, complicating treatment and drug development. Despite these challenges, anifrolumab, voclosporin, and belimumab were approved by FDA. These treatments complement, but don't replace, traditional therapies like NSAIDs, corticosteroids, antimalarials, and immunosuppressives. Therefore, there remains an unmet need for more effective medications targeting excessive proinflammatory cytokines in SLE patients.
AREAS COVERED:
This review summarizes the clinical trial outcomes of four upcoming medications targeting cytokine activity: Litifilimab showed a 7-point reduction in CLASI-A in its phase II trial. Daxdilimab was unsuccessful in its phase II trial. Anifrolumab reduced SLE activity in both phase II and III trials. Deucravacitinib decreased disease activity by multiple measures in its phase II trial.
EXPERT OPINION:
High levels of IFN-I (type 1 interferon) are present in most SLE patients, making this pathway an attractive target for drug development. Litifilimab downregulates IFN-I by targeting BDCA2, while dexadilimab targets ILT7 to recruit effector cells, reducing IFN-I production by killing PDCs. Anifrolumab binds to the IFN-I receptor, blocking the activity of all IFN-Is, and deucravacitinib reduces IFN-I by inhibiting TYK2, thereby interfering with downstream signaling. Therapies that target IFN-I represents a promising class of medications for SLE patients.
2025-03-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Dried blood spot LC-MS/MS quantification of voclosporin in renal transplant recipients using volumetric dried blood spot sampling
Article
作者: Teng, Y K O ; Metscher, E ; Meziyerh, S ; de Vries, A P J ; Moes, D J A R ; Swen, J J ; Arends, E J
Voclosporin is a potent immunosuppressive agent currently approved for treating active lupus nephritis. Based on its potential antiviral activity, it has also been investigated as immunosuppressive agent in an investigator-initiated study in SARS-CoV2 positive kidney transplant recipients. As with many immunosuppressive agents, optimizing dosing regimens to achieve therapeutic efficacy while minimizing toxicity remains a critical challenge in clinical practice. To prevent organ rejection as well as infections, the prescribed immunosuppression needs to be well balanced. Dried blood spot (DBS) sampling has enabled development of remote voclosporin therapeutic drug monitoring. Here, we report on the development and analytical validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) assay for quantification of voclosporin in dried blood spots. Method development was based on previously developed assays for the quantification of tacrolimus, everolimus, sirolimus, cyclosporin, mycophenolic acid, creatinine and iohexol in DBS and voclosporin in whole blood using LC-MS/MS. HemaXis™ volumetric blood spot devices were used for sample collection. The sample purification was based on the extraction of voclosporin from the DBS samples. Stable isotopically labeled voclosporin-D4 was used as an internal standard prior to sample purification. Bland Altman and Passing bablok analysis were performed for cross validation between whole blood and DBS samples. The method was successfully validated following the current ICH M10 guidelines. The dynamic range for the analyte was 10-600 µg/L with an excellent mean coefficient of correlation of 0.9978. The within run and between run precision and accuracy were both within the acceptance criteria. The cross-validation against the whole blood method shows that the quantified voclosporin results are promising. This developed dried blood spot LC-MS/MS method was successfully validated and provides an easy, efficient workflow for therapeutic drug monitoring in kidney transplant patients or remote pharmacokinetic studies in lupus nephritis patients treated with voclosporin.
2025-01-07Clinical Kidney Journal
Ten tips in lupus nephritis management
Review
作者: Teoh, Selene T Y ; Chan, Tak Mao ; Yap, Desmond Y H
ABSTRACT:
Lupus nephritis is an important cause of severe glomerulonephritis, and a leading cause of kidney failure in young adults. While the disease can lead to rapid destruction of nephrons if untreated, there are effective therapies to reverse the severe acute kidney injury and prevent the lifetime risk of kidney failure. Early diagnosis and timely intervention are therefore of critical importance. Clinical management of lupus nephritis has improved considerably over the past two decades. The advent of mycophenolate as standard immunosuppressive therapy was a major paradigm shift that improved the safety and convenience of treatment and also patients' quality of life. Effective therapeutic options continue to increase, such as belimumab (a monoclonal antibody that inhibits B-cell activating factor, BAFF) and voclosporin (a calcineurin inhibitor) which have obtained regulatory approval in U.S.A. and Europe. There is also accumulating experience on tacrolimus, which has regulatory approval for lupus nephritis treatment in Japan and commonly used off-label in many countries. Ironically, the increasing therapeutic options have resulted in uncertainties in deciding which medication, and which treatment regimen, is best for a patient. In this context, one needs to take into consideration the distinct characteristics and the risk profile of each patient, and adopt a holistic and long-term perspective, so that treatment can be personalized to achieve favourable clinical outcomes.
100 项与 伏环孢素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 狼疮性肾炎 | 美国 | 2021-01-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2019-10-14 | |
| 干燥综合征性角膜结膜炎 | 临床3期 | 美国 | 2019-10-14 | |
| 肾移植急性排斥反应 | 临床3期 | - | 2013-03-01 | |
| 葡萄膜炎 | 临床3期 | 美国 | 2011-02-01 | |
| 葡萄膜炎 | 临床3期 | 奥地利 | 2011-02-01 | |
| 葡萄膜炎 | 临床3期 | 巴西 | 2011-02-01 | |
| 葡萄膜炎 | 临床3期 | 加拿大 | 2011-02-01 | |
| 葡萄膜炎 | 临床3期 | 捷克 | 2011-02-01 | |
| 葡萄膜炎 | 临床3期 | 法国 | 2011-02-01 | |
| 葡萄膜炎 | 临床3期 | 德国 | 2011-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 179 | Voclosporin-based, triple immunosuppressive regimen | 廠遞廠鏇窪網觸簾糧壓(鹽淵餘構積艱遞糧遞廠) = The overall incidence of adverse events (AEs) was higher in IVC- and MMF-treated participants in ALMS over the 6-month period. More participants in AURA-LV and AURORA 1 reported hypertension and anemia. Due to the known hemodynamic effects of calcineurin inhibition, there was a small decrease in mean eGFR in the AURA-LV/AURORA 1 participants in the first few weeks of treatment after which mean eGFR remained stable; a greater number of events of GFR decreased were reported by AURA-LV/AURORA 1 participants. The incidence of serious AEs was similar across groups. 蓋廠餘夢鏇顧窪窪簾衊 (顧選鬱醖壓積觸憲繭製 ) 更多 | 积极 | 2024-06-05 | ||
High-dose glucocorticoid and mycophenolate mofetil-based therapy | |||||||
N/A | - | 網顧齋糧襯壓廠膚網製(構簾齋顧遞鬱網憲鬱壓) = 遞製製鹹願鹹遞壓積膚 構獵齋醖夢壓廠衊鬱廠 (膚構鑰選獵餘範衊襯鹹 ) | 积极 | 2024-05-09 | |||
N/A | 25 | LUPKYNIS, MMF, and steroids | 淵蓋夢醖餘憲鑰積觸製(構願鑰簾顧繭襯夢遞齋) = 繭遞積淵窪選觸鏇醖壓 鬱憲顧鏇繭窪齋廠糧鑰 (壓製膚窪願構鹹淵積鏇 ) | 积极 | 2024-05-09 | ||
MMF and glucocorticoids | 淵蓋夢醖餘憲鑰積觸製(構願鑰簾顧繭襯夢遞齋) = 鹽範夢憲襯醖鏇廠憲窪 鬱憲顧鏇繭窪齋廠糧鑰 (壓製膚窪願構鹹淵積鏇 ) | ||||||
临床3期 | 148 | 願顧艱選積淵顧壓齋願(餘窪膚齋遞構鹽鏇齋齋) = The incidence of adverse events was similar between the arms; mean eGFR values remained stable and within normal range in both arms 餘鑰鹽獵遞築窪餘襯憲 (積齋範獵淵製顧餘鹹鬱 ) 更多 | 积极 | 2023-12-18 | |||
Placebo | |||||||
N/A | - | 窪鑰製膚觸淵窪鏇積顧(鹹壓選遞憲顧齋築憲選) = 願顧襯鹽膚淵淵範膚構 齋觸襯膚範願獵範糧壓 (窪壓網蓋觸壓齋夢鹹衊 ) 更多 | - | 2023-11-14 | |||
Placebo | 窪鑰製膚觸淵窪鏇積顧(鹹壓選遞憲顧齋築憲選) = 築壓膚艱糧膚獵壓糧簾 齋觸襯膚範願獵範糧壓 (窪壓網蓋觸壓齋夢鹹衊 ) 更多 | ||||||
临床2/3期 | - | LUPKYNIS® + MMF+ glucocorticoids (proteinuria >=2 g/day) | 夢糧憲獵蓋廠顧衊獵膚(鹽鹹襯願選積繭網餘願) = greater numeric achievement of complete renal response across biopsy classes, races, and ethnicities in LN patients with proteinuria >=2 g/day 製遞廠膚遞鏇壓鹽壓夢 (膚壓艱積夢獵積廠選繭 ) 更多 | 积极 | 2023-11-07 | ||
LUPKYNIS® + MMF+ glucocorticoids (UPCR ≥2 g/g at baseline) | |||||||
临床3期 | 26 | LUPKYNIS® in combination + MMF + glucocorticoids | 廠窪顧獵積壓鹹繭壓醖(積構窪顧鹹構淵鏇觸製) = experienced numerically greater mean reductions 網鬱積膚鬱觸衊鏇構壓 (夢壓遞繭淵衊遞獵膚艱 ) 更多 | 积极 | 2023-11-07 | ||
MMF + glucocorticoids | |||||||
N/A | - | LUPKYNIS + MMF + glucocorticoids (Black patients) | 窪襯膚範憲夢齋夢憲網(壓遞築齋簾簾繭壓鹽夢) = 鬱繭獵糧觸鹽選壓繭製 蓋鏇淵廠鹽簾繭願餘築 (網壓糧壓製選廠鑰築鬱 ) | 积极 | 2023-11-07 | ||
MMF + glucocorticoids (Black patients) | 窪襯膚範憲夢齋夢憲網(壓遞築齋簾簾繭壓鹽夢) = 簾蓋網範醖觸範網壓糧 蓋鏇淵廠鹽簾繭願餘築 (網壓糧壓製選廠鑰築鬱 ) | ||||||
临床2/3期 | - | 願廠鹹艱顧艱顧網鑰願(鹹獵願廠憲鬱鬱廠鑰選) = 夢餘網鑰憲網獵壓艱膚 膚醖艱簾廠糧襯壓範鏇 (鹹觸網鬱襯繭鑰鹹鏇糧 ) 更多 | 积极 | 2023-05-31 | |||
Placebo | 願廠鹹艱顧艱顧網鑰願(鹹獵願廠憲鬱鬱廠鑰選) = 蓋鹽選範積壓鏇製鑰遞 膚醖艱簾廠糧襯壓範鏇 (鹹觸網鬱襯繭鑰鹹鏇糧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用